Testis Sparing Surgery in Pediatric Testicular Tumors

• Published in: Cancers Vol. 12; no. 10; p. 2867
• Main Authors: Kooij, Cezanne D, Hulsker, Caroline C C, Kranendonk, Mariëtte E G, Zsiros, József, Littooij, Annemieke S, Looijenga, Leendert H J, Klijn, Aart J, Mavinkurve-Groothuis, Annelies M C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.10.2020; MDPI
• Subjects: Age; Atrophy; Benign; Biomarkers; Cancer in children; Care and treatment; Case reports; Cysts; Fertility; Patient outcomes; Patients; Pediatrics; Population; Quality of life; Review; Surgery; Teenagers; Testes; Testicular cancer; Tumors; Netherlands; United States > US; recurrence; Testis sparing surgery; testicular atrophy; testicular tumors; germ cell tumor; algorithm; pediatric
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12102867

The purpose of this review is to evaluate the outcomes of testis sparing surgery (TSS) and to investigate under which circumstances TSS can be considered a safe treatment option in pediatric patients with testicular tumors. A database search was performed in Cochrane, Pubmed, and Embase for studies that focused on TSS as treatment for testicular tumors in the pediatric population, excluding reviews and single case reports. Twenty studies, describing the surgical treatment of 777 patients with testicular tumors, were included in the analysis. The majority of pediatric patients with benign germ cell tumors (GCTs) (mean age: 3.7 years) and sex cord-stromal tumors (SCSTs) (mean age: 6.6 years) were treated with TSS, 61.9% and 61.2%, respectively. No cases of testicular atrophy occurred. Four of the benign GCTs, i.e., three teratomas and one epidermoid cyst, recurred. No cases of recurrence were reported in patients with SCSTs. Of the 243 malignant GCTs (mean age: 4.2 years), only one patient had TSS (0.4%). TSS is a safe treatment option for prepubertal patients less than 12 years of age with benign GCTs and low grade SCSTs.